FM (chemotherapy)

FM in the context of chemotherapy means a chemotherapy regimen used as first-line therapy in indolent lymphomas. In combination with rituximab it is called R-FM or RFM or FM-R or FMR.

The [R]-FM regimen consists of:

  1. (R)ituximab - an anti-CD20 monoclonal antibody that is able to kill both normal B cells and malignant ones;
  2. (F)ludarabine - an antimetabolite;
  3. (M)itoxantrone - a synthetic antracycline analogue (an antraquinone) that is able to intercalate DNA and prevent mitosis.[1]

This regimen is also sometimes used in some autoimmune disorders that are inherently sensitive to rituximab, fludarabine and mitoxantrone in monotherapies (e.g. multiple sclerosis).

Dosing regimen
DrugDoseModeDays
(R)ituximab375 mg/m2IV infusionDay 1
(F)ludarabine25 mg/m2IV infusionDays 1-3
(M)itoxantrone10 mg/m2IV infusionDay 1

References
  1. Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.